行情

FATE

FATE

Fate
NASDAQ

实时行情|Nasdaq Last Sale

14.71
+0.18
+1.24%
盘后: 14.66 -0.05 -0.35% 16:11 10/22 EDT
开盘
14.66
昨收
14.53
最高
14.93
最低
14.36
成交量
51.91万
成交额
--
52周最高
22.82
52周最低
11.00
市值
11.06亿
市盈率(TTM)
-12.0386
分时
5日
1月
3月
1年
5年

分析师评级

14位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

FATE 新闻

  • 沪指小幅震荡 约翰逊月底“脱欧”计划落空
  • 新浪财经.20分钟前
  • 美众议院投票通过法案:要求空壳公司披露真正拥有者
  • 澎湃新闻.1小时前
  • 新股聚焦 | 横跨中美,九阳母公司JS环球再掀巨浪
  • 华盛通.1小时前
  • 约翰逊月底"脱欧"计划泡汤 提前大选或成唯一途径
  • 海外网.2小时前

更多

所属板块

生物技术和医学研究
+0.44%
制药与医学研究
+0.60%

热门股票

名称
价格
涨跌幅

FATE 简况

Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.
展开

Webull提供Fate Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。